[go: up one dir, main page]

WO2004050706A3 - Regulatory t-cells - Google Patents

Regulatory t-cells Download PDF

Info

Publication number
WO2004050706A3
WO2004050706A3 PCT/GB2003/005279 GB0305279W WO2004050706A3 WO 2004050706 A3 WO2004050706 A3 WO 2004050706A3 GB 0305279 W GB0305279 W GB 0305279W WO 2004050706 A3 WO2004050706 A3 WO 2004050706A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
regulatory
relates
recruit
chemokines
Prior art date
Application number
PCT/GB2003/005279
Other languages
French (fr)
Other versions
WO2004050706A2 (en
Inventor
Alexander Betz
Marinos Kallikourdis
Original Assignee
Medical Res Council
Alexander Betz
Marinos Kallikourdis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228190A external-priority patent/GB0228190D0/en
Priority claimed from GB0323014A external-priority patent/GB0323014D0/en
Application filed by Medical Res Council, Alexander Betz, Marinos Kallikourdis filed Critical Medical Res Council
Priority to AU2003285586A priority Critical patent/AU2003285586A1/en
Publication of WO2004050706A2 publication Critical patent/WO2004050706A2/en
Publication of WO2004050706A3 publication Critical patent/WO2004050706A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a sub-group of T.cells. In particular the invention relates to characteristics of regulatory T-cells which define them as such. The invention also relates to the uses of such T-cells, compositions comprising them and chemokines which recruit them in the modulation of an immune response.
PCT/GB2003/005279 2002-12-03 2003-12-03 Regulatory t-cells WO2004050706A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003285586A AU2003285586A1 (en) 2002-12-03 2003-12-03 Regulatory t-cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0228190A GB0228190D0 (en) 2002-12-03 2002-12-03 T-cells
GB0228190.5 2002-12-03
GB0323014A GB0323014D0 (en) 2003-10-01 2003-10-01 T-cells
GB0323014.1 2003-10-01

Publications (2)

Publication Number Publication Date
WO2004050706A2 WO2004050706A2 (en) 2004-06-17
WO2004050706A3 true WO2004050706A3 (en) 2004-09-16

Family

ID=32472153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/005279 WO2004050706A2 (en) 2002-12-03 2003-12-03 Regulatory t-cells

Country Status (2)

Country Link
AU (1) AU2003285586A1 (en)
WO (1) WO2004050706A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015989B1 (en) * 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE
EP1826278A1 (en) 2006-02-28 2007-08-29 Epiontis GmbH Epigenetic modification of the loci for camta1 and/or foxp3 as a marker for cancer treatment
GB0604170D0 (en) * 2006-03-02 2006-04-12 Antitope Ltd T cell assays
WO2007099341A1 (en) * 2006-03-02 2007-09-07 Antitope Limited T cell assays
US20100017370A1 (en) * 2006-10-11 2010-01-21 Antitope Limited T cell epitope databases
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
EP2141245A1 (en) 2008-07-03 2010-01-06 Ivana Türbachova DNA methylation analysis of regulatory T cells through DNA-methylation analysis of the TSDR region of the gene foxP3
DK2199411T3 (en) 2008-12-16 2015-08-03 Epiontis Gmbh Epigenetic markers for the identification of CD3-positive T lymphocytes
PL2248913T3 (en) 2009-04-28 2017-04-28 Epiontis Gmbh GNLY as epigenetic marker for the identification of CD56-expressing natural killer cells
EP2625288B1 (en) 2010-10-08 2016-05-25 Epiontis GmbH Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes
GB201112586D0 (en) 2011-07-22 2011-09-07 Epiontis Gmbh Epigenetic marker for the identification of natural killer cells
DK2788510T3 (en) 2012-03-12 2017-03-20 Epiontis Gmbh Epigenetic marker for identification of CD3CD4-positive T lymphocytes
EP2970909A4 (en) * 2013-03-15 2017-02-15 The University of Chicago Methods and compositions related to t-cell activity
EP2986735B1 (en) 2013-04-19 2019-03-06 Epiontis GmbH Method for identifying the quantitative composition of blood cells in a sample
CN110241081B (en) * 2019-06-12 2021-06-11 深圳爱生再生医学科技有限公司 Treg cell amplification medium and in-vitro amplification method

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038559A1 (en) * 1995-05-31 1996-12-05 Dana Farber Cancer Institute Chemokine n-terminal deletion mutations
WO1998049560A1 (en) * 1997-04-25 1998-11-05 The University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
US5869081A (en) * 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
WO1999015666A2 (en) * 1995-06-07 1999-04-01 Icos Corporation Macrophage derived chemokine (mdc), mdc analogs, mdc inhibitor sustances, and uses thereof
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO1999053033A1 (en) * 1998-04-16 1999-10-21 Vanderbilt University Methods and compositions for high yield production of eukaryotic proteins
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
WO2000042856A1 (en) * 1999-01-22 2000-07-27 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2000076320A1 (en) * 1999-06-15 2000-12-21 The Trustees Of Columbia University In The City Of New York Generation of antigen specific t suppressor cells for treatment of rejection
WO2001026679A2 (en) * 1999-10-08 2001-04-19 Li Zhang T-cells and molecules involved in immune regulation
WO2001057074A1 (en) * 2000-02-04 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
US6383746B1 (en) * 1997-10-23 2002-05-07 The United States Of America As Represented By The Department Of Health And Human Services Functional promoter for CCR5
US20020090357A1 (en) * 2000-10-04 2002-07-11 Barrat Franck J. Regulatory T cells; methods
WO2003022885A1 (en) * 2001-09-06 2003-03-20 Medical Research Council Chemokines
WO2003066072A2 (en) * 2002-02-07 2003-08-14 Universite Pierre Et Marie Curie (Paris Vi) Cell therapy using immunoregulatory t-cells

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038559A1 (en) * 1995-05-31 1996-12-05 Dana Farber Cancer Institute Chemokine n-terminal deletion mutations
WO1999015666A2 (en) * 1995-06-07 1999-04-01 Icos Corporation Macrophage derived chemokine (mdc), mdc analogs, mdc inhibitor sustances, and uses thereof
US5869081A (en) * 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
WO1998049560A1 (en) * 1997-04-25 1998-11-05 The University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
US6383746B1 (en) * 1997-10-23 2002-05-07 The United States Of America As Represented By The Department Of Health And Human Services Functional promoter for CCR5
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
WO1999053033A1 (en) * 1998-04-16 1999-10-21 Vanderbilt University Methods and compositions for high yield production of eukaryotic proteins
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
WO2000042856A1 (en) * 1999-01-22 2000-07-27 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2000076320A1 (en) * 1999-06-15 2000-12-21 The Trustees Of Columbia University In The City Of New York Generation of antigen specific t suppressor cells for treatment of rejection
WO2001026679A2 (en) * 1999-10-08 2001-04-19 Li Zhang T-cells and molecules involved in immune regulation
WO2001057074A1 (en) * 2000-02-04 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
US20020090357A1 (en) * 2000-10-04 2002-07-11 Barrat Franck J. Regulatory T cells; methods
WO2003022885A1 (en) * 2001-09-06 2003-03-20 Medical Research Council Chemokines
WO2003066072A2 (en) * 2002-02-07 2003-08-14 Universite Pierre Et Marie Curie (Paris Vi) Cell therapy using immunoregulatory t-cells

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BYSTRY R S ET AL: "B cells and professional APCs recruit regulatory T cells via CCL4.", NATURE IMMUNOLOGY. UNITED STATES DEC 2001, vol. 2, no. 12, December 2001 (2001-12-01), pages 1126 - 1132, XP001120877, ISSN: 1529-2908 *
HOLDSTOCK G ET AL: "EFFECTS OF TESTOSTERONE ESTRADIOL AND PROGESTERONE ON IMMUNE REGULATION", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 47, no. 2, 1982, pages 449 - 456, XP009032225, ISSN: 0009-9104 *
KHATTRI ROLI ET AL: "An essential role for Scurfin in CD4+CD25+ T regulatory cells.", NATURE IMMUNOLOGY, vol. 4, no. 4, April 2003 (2003-04-01), pages 337 - 342, XP001181987, ISSN: 1529-2908 (ISSN print) *
LEVINGS MEGAN K ET AL: "Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 193, no. 11, 4 June 2001 (2001-06-04), pages 1295 - 1301, XP002210571, ISSN: 0022-1007 *
MCGUIRK PETER ET AL: "Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: A novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 195, no. 2, 21 January 2002 (2002-01-21), pages 221 - 231, XP002271535, ISSN: 0022-1007 *
ONUFFER J J ET AL: "Chemokines, chemokine receptors and small-molecule antagonists: recent developments", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 10, 1 October 2002 (2002-10-01), pages 459 - 467, XP004383612, ISSN: 0165-6147 *
SEBASTIANI S ET AL: "Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 JAN 2001, vol. 166, no. 2, 15 January 2001 (2001-01-15), pages 996 - 1002, XP002271536, ISSN: 0022-1767 *
THORNTON A M ET AL: "Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 JAN 2000, vol. 164, no. 1, 1 January 2000 (2000-01-01), pages 183 - 190, XP002284549, ISSN: 0022-1767 *
THORNTON ANGELA M ET AL: "Cytokine and costimulatory requirements for induction of CD4+CD25+ suppressor effector function", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), Annual Meeting of the Professional Research Scientists on Experimental Biology;New Orleans, Louisiana, USA; April 20-24, 2002, pages A716, XP009032206, ISSN: 0892-6638 *
YAMAGIWA S ET AL: "A role for TGF-beta in the generation and expansion of CD4+CD25+ regulator y T cells from human peripheral blood", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 2001, pages 7282 - 7289, XP002969113, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2003285586A8 (en) 2004-06-23
WO2004050706A2 (en) 2004-06-17
AU2003285586A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2004050706A3 (en) Regulatory t-cells
WO2004078120A3 (en) Collagen compositions and biomaterials
WO2004037194A3 (en) Novel compositions with chitinase activity
MXPA03008714A (en) Sequenced polymers and cosmetic compositions comprising the same.
IL161229A0 (en) Methods and compositions relating to restricted expression lentiviral vectors and their applications.
WO2005040389A3 (en) Compositions with chitinase activity
AU2003220240A1 (en) Boswellin compositions enhanced with 3-beta-acety1-11-keto-beta-boswellic acid (akba), industrial manufacture and their uses
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
AU2003216058A8 (en) Mammalian neural stem cells, compositions and uses thereof
WO2005058283A3 (en) Stabilised compositions of factor vii polypeptides
EP1623011A4 (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2002071874A3 (en) Composition improving age-related physiological deficits and increasing longevity
AU2003290794A1 (en) Curable epoxy compositions, methods and articles made therefrom
AU2002314825A1 (en) Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
MX244969B (en) Modified aminoplast crosslinkers and power coating compositions containing such crosslinkers.
AU2003244100A1 (en) Acrylic resin composition, organosiloxane resin composition and laminates made by using them
WO2005037470A3 (en) Encapsulated nanoparticles, products containing the same, and methods for using the same
AU2003296553A1 (en) Increase of the immune response by substances influencing the function of natural killer cells
IL172653A0 (en) Novel ??-actin and rps21 promoters and uses thereof
WO2002005643A3 (en) Biocide compositions and methods and systems employing same
WO2003090521A3 (en) Tomato plants that exhibit resistance to botrytis cinerea
WO2002085105A3 (en) Tomato plants that exhibit resistance to $i(botrytis cinerea)
WO2004003149A8 (en) Cngh0005 polypeptides, antibodies, compositions, methods and uses
AU2003221053A1 (en) Unsaturated polybranched compounds, curable compositions containing the same and cured articles thereof
WO2003069003A3 (en) Thin strips made of aluminium-iron alloy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP